MINISO Group reports Q3 results with an adjusted net profit of RMB 767 million, a year-over-year increase of 11.7%; Hengrui Pharma: nine drugs approved for clinical trials.
Material Events:
Fosun Pharma (02196): Registration application for Fumaning drug accepted.
Hengrui Pharma (01276): Nine drugs approved for clinical trials
China Jinmao (00817) subsidiary plans to list for sale 100% equity interest in Jinmao (Sanya) Tourism Co., Ltd. at a floor price of RMB 2.2646 billion.
Boretton (01333) Unveils New Autonomous Mining Truck
CSPC Pharma (01093): Selective 5-HT2A receptor agonist (SYH2056 tablet) receives clinical trial approval in China.
BAIC Motor (01958) Plans to Sell 51% Stake in BAIC International for Approximately RMB 1.608 Billion
CITIC Bank (00998): Wholly-Owned Subsidiary CITIC Gold Investment Receives Approval for Commencement of Operations
Operating performance:
Miniso (09896) announced its third-quarter financial results, with an adjusted net profit of RMB 767 million, representing a year-on-year increase of 11.7%.
Pudatech (00650) achieved sales revenue of approximately HKD 77.568 million in the first half of the year, with multiple core semiconductor equipment products securing significant orders.
UJOM Holding (01948) reported total billings of approximately RMB 11.863 billion generated from its online marketing solutions business in the first nine months, representing a year-over-year increase of approximately 35.3%.
South Textile Holdings (01982) announced its interim results, with profit attributable to owners of the company amounting to HKD 336 million, reflecting a year-over-year growth of 12.7%.
International Commercial Settlement (00147) issued a profit warning, expecting the net comprehensive loss for the interim period to increase by approximately 72% year-over-year.
